These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 34786649)
1. Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid. Wang X; Vilchez RA Clin Pharmacokinet; 2022 Apr; 61(4):515-526. PubMed ID: 34786649 [TBL] [Abstract][Full Text] [Related]
2. Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events. Wang X; Tseng J; Mak C; Poola N; Vilchez RA Clin Pharmacokinet; 2021 Dec; 60(12):1557-1567. PubMed ID: 34125423 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes. Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Zacharias HD; Zacharias AP; Gluud LL; Morgan MY Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790 [TBL] [Abstract][Full Text] [Related]
5. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542 [TBL] [Abstract][Full Text] [Related]
6. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Jalan R; Wright G; Davies NA; Hodges SJ Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190 [TBL] [Abstract][Full Text] [Related]
7. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490 [TBL] [Abstract][Full Text] [Related]
8. Ornithine phenylacetate revisited. Jover-Cobos M; Noiret L; Sharifi Y; Jalan R Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516 [TBL] [Abstract][Full Text] [Related]
9. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure. Kristiansen RG Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377 [TBL] [Abstract][Full Text] [Related]
15. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823 [TBL] [Abstract][Full Text] [Related]
16. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis. Butterworth RF Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246 [TBL] [Abstract][Full Text] [Related]
17. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway. Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. Kircheis G; Lüth S Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424 [TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. Chen MF; Li RC; Chen CH; Gao XC Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319 [TBL] [Abstract][Full Text] [Related]
20. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]